Latest Articlesddd
Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX …
Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic …
Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS), announced positive results from the pivotal …
A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg …
An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for …
We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the …
Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of …
Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania. …
Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise …
Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore …
Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other …
About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …
Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …
Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …
The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …
Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …
Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …
XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …
It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
